References
- Arunlakshana O., Schild H.O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959; 14: 48–58
- Bonner T.I., Buckley N.J., Young A.C., Brann M.R. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987; 237: 527–532
- Bonner T.I., Young A.C., Brann M.R., Buckley N.J. Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1988; 1: 403–410
- Dörje F., Wess J., Lambrecht G., Tacke R., Mutschler E., Brann M.R. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 1991; 256: 727–733
- Eglen R.M., Michel A.D., Montgomery W.W., Kunysz E.A., Machado C.A., Whiting R.L. The interaction of parafluorohexahydrosiladiphenidol at muscarinic receptors in vitro. Br. J. Pharmacol. 1990; 99: 637–642
- Hu J., El-Fakahany E.E. Selectivity of McN-A-343 in stimulating phosphoinositide hydrolysis mediated by M1 muscarinic receptors. Mol. Pharmacol. 1990; 38: 895–903
- Hulme E.C., Birdsall N.J.M., Buckley N.J. Muscarinic receptor subtypes. Annu. Rev. Pharmacol. Toxicol. 1990; 30: 633–673
- Kromer W., Baron E., Beinborn M., Boer R., Eltze M. Characterization of the muscarinic receptor type on paracrine cells activated by McN-A-343 in the mouse isolated stomach. Naunyn. Schmiedebergs Arch. Pharmakol. 1990; 34: 165–170
- Lambrecht G., Feifel R., Forth B., Strohmann C., Tacke R., Mutschler E. p-Fluoro-hexahydro-sila-difenidol: The first M2β-selective muscarinic antagonist. Eur. J. Pharmacol. 1988; 152: 193–194
- Lambrecht G., Feifel R., Wagner-Roeder M., Strohmann C., Zilch H., Tacke R., Waelbroeck M., Christophe J., Boddeke H., Mutschler E. Affinity profiles of hexahydro-sila-difenidol analogues at muscarinic receptor subtypes. Eur. J. Pharmacol. 1989; 168: 71–80
- Mitchelson F., Choo L.K., Darroch S. Muscarinic receptor differentiation. Clin. Exp. Pharmacol. Physiol. 1989; 16: 523–528
- Munson R.J., Rodbard D. Ligand: A versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 1980; 107: 202–239
- Nathanson N.M. Molecular properties of the muscarinic acetylcholine receptor. Annu. Rev. Neurosci. 1987; 10: 195–236
- Pedder E.K., Eveleigh P., Poyner D., Hulme E.C., Birdsall N.J.M. Modulation of the structure-binding relationships of antagonists for muscarinic acetylcholine receptor subtypes. Br. J. Pharmacol. 1991; 103: 1561–1567
- Peralta E.G., Ashkenazi A., Winslow J.W., Smith D.H., Ramachandran J., Capon D.J. Distinct primary structure, ligand binding properties and tissuespecific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987; 6: 3923–3929
- Poyner D.R., Birdsall N.J.M., Curtis C., Eveleigh P., Hulme E.C., Pedder E.K., Wheatley M. Binding and hydrodynamic properties of muscarinic receptor subtypes solubilized in 3-(3-cholamindopropyl)dimethylammonio-2-hydroxyl-1-propanesulfonate. Mol. Pharmcol. 1989; 36: 420–429
- Ransom J.T., Cher H.M., Delmendo R.E., Sharif N.A., Eglen R. Characterization of the m4 muscarinic receptor Ca2+ response in a subclone of PC-12 cells by single cell flow cytometry. J. Biol. Chem. 1991; 266: 11738–11745
- Richards M.H. Pharmacology and second messenger interactions of cloned muscarinic receptors. Biochem. Pharmacol. 1991; 42: 1645–1653